Back to results

Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease

Primary Purpose

Chagas Disease, Heart Diseases

Status

Terminated

Phase

Phase 4

Locations

International

Study Type

Interventional

Intervention

Implantable Cardiac Monitor

Standard of Care

About this trial

This is an interventional treatment trial for Chagas Disease focused on measuring Chagas Disease, Chagasic, Reveal XT, Implantable Cardiac Monitor, ICM

Eligibility Criteria

21 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Have Chagas disease, confirmed by two serological tests.
Provide evidence through any of the following diagnosis methods: Rest ECG, 24 hour Holter monitoring, electrophysiological study, stress test or loop monitoring, at least one electrical disorder consistent with sinus bradycardia greater than 45 and lower than 60 bpm, sinus arrest not greater than 2.0 seconds, second degree atrial sinus block, intraventricular conduction disorders such as right branch, left branch or a bifascicular blockage type, first degree A-V blockage, or of type I second degree AV Block without associated bradycardia, atrial and/or ventricular arrhythmias that do NOT constitute an indication for pacemaker implant, ICD or mapping and radio frequency ablation.
Be asymptomatic or having minimal isolated unspecific symptoms not consistent with cardiac arrest, aborted sudden death, syncope, frequent and recurrent palpitations, cardiac failure, and lower extremity edema.
Have ejection fraction of left ventricle >35%
Be able to give his/her written informed consent.
Subject should be > 21 years old.
Be able to return for follow-up visits as required.

Exclusion Criteria:

Class I or II (according to AHA/HRS/ESC guidelines) indication for final implantation of pacemaker, ICD, or cardiac resynchronizer.
Exhibit extrinsic causes of sinus dysfunction or A-V blockage.
Exhibit infiltrative myocardial diseases such as tumors or associated valvular defects.
Suffer any concurrent disease that may limit the follow up or evaluation.
Suffer aftereffects of cerebral embolism.
Suffer ablation or isolation of pulmonary veins previous to their inclusion in the study.
Not being able or willing to comply with the follow-up schedule.
Have previous lesions of the spinal cord or aftereffects of skull trauma.
Have a record of epilepsy.
Receive pharmacological treatment for other diseases that may modify the autonomic function.
Have a record of myocardial infarction.
History of alcohol abuse or drug addiction.
History of emotional instability, unstable psychiatric disorders or are under treatment for such disorders.
Have previously implanted pacemakers, cardiodefibrillators or CRT systems.
Are included or intend to participate in another study of devices during the course of this study.
Have a clinical condition that may limit life expectancy to < 36 months.
Use of Antiarrhythmic drugs, except Beta Blockers

Sites / Locations

Hospital General de Agudos "Juan Fernandez"
Hospital Interzonal General de Agudos "General José de San Martin"
Fundacion Cardioinfantil
Hospital Militar Central

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Reveal XT plus SOC

Standard of Care

Arm Description

Standard of care treatment plus the Reveal XT Implantable Cardiac Monitor. Treatment will follow the same schedule of the standard of care arm regarding exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months. The addition will be device interrogation at every 6 month exam. Participation will last 36 months.

Standard of care arm as described by exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months. Participation will last 36 months.

Outcomes

Primary Outcome Measures

To compare the time to the physician's decision to treat for electrical disorders (brady/tachyarrhythmias) between the two randomized groups.

The primary endpoint is time to the first decision to implant a device (IPG, CRT-P, ICD or CRT-D) or prescribe anti-arrhythmic drugs.

Secondary Outcome Measures

Summarize the recorded arrhythmic events stored within the ICM (bradyarrhythmia and tachyarrhythmia.

Compute summary statistics for arrhythmic events recorded during follow-up, whether or not related to symptoms, for all patients in the ICM arm, including the total number, distribution (e.g., minimum, maximum, median, quartiles, and standard deviation), number per patient year, number of patients having events and percentage of patients having events. Summary statistics for bradyarrhythmia and tachyarrhythmia events will also be computed separately.

Compute the time duration spent in arrhythmias for ICM patients.

Compute the total duration each ICM patient spends in, 1) atrial arrhythmias and 2) ventricular arrhythmias during the entire follow-up period, and their corresponding distribution (e.g., minimum, maximum, median, quartiles, standard deviation). Compute the average duration each patient spends in an, 1) atrial arrhythmia event, and 2) a ventricular arrhythmia event, and the corresponding distributions.

Compute the incidence of symptomatic arrhythmias in patients with an ICM

Compute the incidence rate of symptomatic arrhythmias in patients with an ICM, overall, and for bradyarrhythmias and tachyarrhythmias separately.

Compare the time to the physician's decision to treat with components of the composite primary endpoint between randomization arms.

Individually compare the time to the physicians' decision to treat with the following between the two randomization arms: A device of any type (IPG, CRT-P, ICD or CRT-D) A pacemaker (IPG) Anti-arrhythmic drug therapy A defibrillator (ICD or CRT-D) or prescribe anti-arrhythmic drug therapy

Compare the mortality rate between randomization arms.

Full Information

NCT ID

NCT01539161

First Posted

February 9, 2012

Last Updated

October 10, 2016

Sponsor

Medtronic Cardiac Rhythm and Heart Failure

1. Study Identification

Unique Protocol Identification Number

NCT01539161

Brief Title

Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease

Official Title

Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease

Study Type

Interventional

2. Study Status

Record Verification Date

October 2016

Overall Recruitment Status

Terminated

Why Stopped

Extremely low enrollment rate

Study Start Date

July 2013 (undefined)

Primary Completion Date

April 2015 (Actual)

Study Completion Date

April 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Medtronic Cardiac Rhythm and Heart Failure

4. Oversight

Data Monitoring Committee

5. Study Description

Brief Summary

The study "Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients with Chagas Disease" is a prospective, multicenter, randomized study that is being conducted at several centers in Latin America with commercially available products. The primary study hypothesis is that patients with implantable cardiac monitors will have a shorter time to the decision to treat for electrical or arrhythmic disorders during the follow-up period. The geography includes Argentina and Colombia.

Detailed Description

The purpose is to study the possible benefit of a superior treatment decision rate for cardiac arrhythmias (brady- and or/ tachyarrhythmias) using an implantable cardiac monitor (ICM) in patients with Chagas Disease diagnosed by serology, who are asymptomatic and/or minimally symptomatic. Patients that meet inclusion criteria of the study will be randomized to standard care or standard care plus ICM. Approximately half of the patients will receive an ICM. All patients will be followed for 36 months. It is expected that the enrollment phase will last 1 year, and that the total study duration will be 4 years. The study is expected to end in 2017. One hundred and two patients are needed for 95% confidence level and 80% statistical power to be randomized into the study, at approximately 5 centers in Latin America. Patients will be considered enrolled once they have signed the Informed Consent. The following additional parameters will also be collected: Recorded arrhythmic events stored within the ICM (bradyarrhythmia and tachyarrhythmia) Time duration spent in arrhythmia and incidence of symptomatic arrhythmias in patients with an ICM. Clinical data on subject outcomes and changes in heart failure as assessed by heart failure hospitalizations, New York Heart Association class and mortality.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Chagas Disease, Heart Diseases

Keywords

Chagas Disease, Chagasic, Reveal XT, Implantable Cardiac Monitor, ICM

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 4

Interventional Study Model

Parallel Assignment

Masking

None (Open Label)

Allocation

Randomized

Enrollment

12 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Reveal XT plus SOC

Arm Type

Experimental

Arm Description

Arm Title

Standard of Care

Arm Type

Active Comparator

Arm Description

Standard of care arm as described by exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months. Participation will last 36 months.

Intervention Type

Device

Intervention Name(s)

Implantable Cardiac Monitor

Other Intervention Name(s)

9529 Reveal XT, 9539 Reveal XT Patient Assistant

Intervention Description

9529 Reveal XT Implantable Cardiac Monitor as well as the use of 9539 Reveal XT Patient Assistant.

Intervention Type

Procedure

Intervention Name(s)

Standard of Care

Other Intervention Name(s)

SOC

Intervention Description

Standard of care arm including exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months.

Primary Outcome Measure Information:

Title

To compare the time to the physician's decision to treat for electrical disorders (brady/tachyarrhythmias) between the two randomized groups.

Description

The primary endpoint is time to the first decision to implant a device (IPG, CRT-P, ICD or CRT-D) or prescribe anti-arrhythmic drugs.

Time Frame

36 months

Secondary Outcome Measure Information:

Title

Summarize the recorded arrhythmic events stored within the ICM (bradyarrhythmia and tachyarrhythmia.

Description

Time Frame

36 months

Title

Compute the time duration spent in arrhythmias for ICM patients.

Description

Time Frame

36 months

Title

Compute the incidence of symptomatic arrhythmias in patients with an ICM

Description

Compute the incidence rate of symptomatic arrhythmias in patients with an ICM, overall, and for bradyarrhythmias and tachyarrhythmias separately.

Time Frame

36 months

Title

Compare the time to the physician's decision to treat with components of the composite primary endpoint between randomization arms.

Description

Time Frame

36 months

Title

Compare the mortality rate between randomization arms.

Description

Compare the mortality rate between randomization arms.

Time Frame

36 months

10. Eligibility

Sex

All

Minimum Age & Unit of Time

21 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Have Chagas disease, confirmed by two serological tests. Provide evidence through any of the following diagnosis methods: Rest ECG, 24 hour Holter monitoring, electrophysiological study, stress test or loop monitoring, at least one electrical disorder consistent with sinus bradycardia greater than 45 and lower than 60 bpm, sinus arrest not greater than 2.0 seconds, second degree atrial sinus block, intraventricular conduction disorders such as right branch, left branch or a bifascicular blockage type, first degree A-V blockage, or of type I second degree AV Block without associated bradycardia, atrial and/or ventricular arrhythmias that do NOT constitute an indication for pacemaker implant, ICD or mapping and radio frequency ablation. Be asymptomatic or having minimal isolated unspecific symptoms not consistent with cardiac arrest, aborted sudden death, syncope, frequent and recurrent palpitations, cardiac failure, and lower extremity edema. Have ejection fraction of left ventricle >35% Be able to give his/her written informed consent. Subject should be > 21 years old. Be able to return for follow-up visits as required. Exclusion Criteria: Class I or II (according to AHA/HRS/ESC guidelines) indication for final implantation of pacemaker, ICD, or cardiac resynchronizer. Exhibit extrinsic causes of sinus dysfunction or A-V blockage. Exhibit infiltrative myocardial diseases such as tumors or associated valvular defects. Suffer any concurrent disease that may limit the follow up or evaluation. Suffer aftereffects of cerebral embolism. Suffer ablation or isolation of pulmonary veins previous to their inclusion in the study. Not being able or willing to comply with the follow-up schedule. Have previous lesions of the spinal cord or aftereffects of skull trauma. Have a record of epilepsy. Receive pharmacological treatment for other diseases that may modify the autonomic function. Have a record of myocardial infarction. History of alcohol abuse or drug addiction. History of emotional instability, unstable psychiatric disorders or are under treatment for such disorders. Have previously implanted pacemakers, cardiodefibrillators or CRT systems. Are included or intend to participate in another study of devices during the course of this study. Have a clinical condition that may limit life expectancy to < 36 months. Use of Antiarrhythmic drugs, except Beta Blockers

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Claudio Muratore, MD

Organizational Affiliation

Medtronic

Official's Role

Study Chair

First Name & Middle Initial & Last Name & Degree

Diego Venagas, MD

Organizational Affiliation

Colombia

Official's Role

Principal Investigator

First Name & Middle Initial & Last Name & Degree

Jose Carlos Pachon Mateos, MD

Organizational Affiliation

Brazil

Official's Role

Study Chair

First Name & Middle Initial & Last Name & Degree

Luis Medesani, MD

Organizational Affiliation

Argentina - Hospital Interzonal Gernal de Agudos "General José de San Martin"

Official's Role

Principal Investigator

Facility Information:

Facility Name

Hospital General de Agudos "Juan Fernandez"

City

Buenos Aires

State/Province

Caba

Country

Argentina

Facility Name

Hospital Interzonal General de Agudos "General José de San Martin"

City

La Plata

Country

Argentina

Facility Name

Fundacion Cardioinfantil

City

Bogota

Country

Colombia

Facility Name

Hospital Militar Central

City

Bogota

Country

Colombia

12. IPD Sharing Statement

Learn more about this trial

Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease

We'll reach out to this number within 24 hrs